UK pharmaceutical giant AstraZeneca (LON:AZN) reaffirmed its target of generating $80 billion of revenue in 2030. The firm made the pledge alongside Q2 and H1 earnings which topped analysts’ forecasts. Q2 earnings top forecasts For the six months to June, Astra reported revenue of $30.67 billion, up 9.4% on a headline basis and 6% at … Continue reading AstraZeneca reaffirms 2030 revenue target